Treatment of Piperacillin-Tazobactam-Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials.
John CaoYanina DubrovskayaJustin SiegfriedArnold DecanoDana MazoSarah HochmanIoannis M ZacharioudakisJonathan SoSadie SolomonJohn PapadopoulosKassandra MarshPublished in: Open forum infectious diseases (2023)
Our study did not find improved clinical outcomes with targeted carbapenem therapy for TZP-NS/CRO-S infections. Carbapenem-sparing agents may be considered to spare carbapenems in noncritically ill patients similar to those included in our cohort.
Keyphrases
- gram negative
- acinetobacter baumannii
- klebsiella pneumoniae
- multidrug resistant
- end stage renal disease
- drug resistant
- chronic kidney disease
- pseudomonas aeruginosa
- newly diagnosed
- ejection fraction
- escherichia coli
- peritoneal dialysis
- prognostic factors
- cancer therapy
- patient reported outcomes
- cystic fibrosis
- dengue virus
- patient reported